General Inception Acquires Enable Medicine to Drive AI-Led Drug Discovery Breakthroughs

General Inception, a global biotech company igniter, has acquired Enable Medicine, a leader in Artificial Intelligence-driven biological research, in a strategic equity partnership aimed at revolutionizing drug discovery. This collaboration combines Enable’s generative AI models, which explore vast cellular atlases for new therapeutic insights, with General Inception’s drug development expertise.

Building on their success with Ennovate Pharma SAS, the partnership will enhance capabilities in autoimmune and inflammatory disease research, empowering biopharmaceutical innovation worldwide. Financial terms remain undisclosed. 

Aaron Mayer, co-founder and Chief Scientific Officer of Enable Medicine, said: “Generative biological search of our Atlas of disease is unlocking the next generation of drug discovery. By working with General Inception, and its global network of experienced executives and drug developers, we will be able to jointly accelerate target discovery, develop optimal patient treatment strategies, and improve clinical drug positioning.”

The strategic partnership will give General Inception greater access to Enable Medicine’s biological data platform, benefiting life science and biopharmaceutical researchers, while Enable Medicine will benefit from General Inception’s drug development expertise and biotech ecosystem.

Power of generative biological search

Enable Medicine harnesses the revolutionary capabilities of AI to guide novel insights into biology and medicine. The platform unlocks the power of generative biological search, which uses cutting-edge AI models to search maps of disease for novel drug targets and indications. The approach prioritizes indexing high quality multimodal cellular data to enable the research community and pharmaceutical industry to quickly answer complex questions about disease.

Proven track record

The two companies first collaborated in 2023, when they established Ennovate Pharma, which develops precision therapeutics for autoimmune and inflammatory diseases by leveraging biological atlases to identify, stratify and understand why certain patients do not respond to current therapies.

Using Enable’s data platform and AI analysis tools, they revealed vital clinical insights about why some patients with certain autoimmune diseases fail to respond to standard-of-care treatments. After 18 months, they are addressing refractory and non-responder populations in autoimmune disease and have identified and validated several highly promising targets.

Professor James Zou, who is an AI pioneer in life sciences and medicine, and is a member of Enable’s Scientific Advisory Board, said: “Leveraging AI to help cure seemingly incurable diseases is possible, but only if we have the right data that can identify the correct biological targets in the first place. Organizing such data and finding such targets has historically been a real challenge. Enable Medicine has developed a hugely powerful new way of indexing and interrogating biological data to speed up this vital process. This partnership with General Inception will ensure its transformative technology can be put to use by many top researchers, working in a wide range of areas including cancer, autoimmune and inflammatory disease.”